The work led by UB bioengineers Ruogang Zhao and Yun Wu may help discover new drugs to treat pulmonary fibrosis, a severe lung disease that has no cure.
Household members of anyone who recently tested positive for COVID-19 are being recruited for Regeneron’s national clinical trial of the investigational antibody cocktail REGN-COV2.
The partnership is working to advance affordable, new antivirals and vaccines for neglected infectious diseases such as the dengue, Zika and Chikungunya viruses.
The SUNY Distinguished Professor is the recipient of the 2020 Distinguished Pharmaceutical Scientist Award from the American Association of Pharmaceutical Sciences.